<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03083184</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0307</org_study_id>
    <secondary_id>2016-A00180-51</secondary_id>
    <nct_id>NCT03083184</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of an inTerdialytic &quot;Ethanol 40% v/v - enoxapaRin 1000 U/mL&quot; Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients</brief_title>
  <acronym>ETERNITY</acronym>
  <official_title>Evaluation of the Efficacy of an inTerdialytic &quot;Ethanol 40% v/v - enoxapaRin 1000 U/mL&quot; Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients: a mulTi-centre, Randomized, Single Blind, Parallel Group studY (ETERNITY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH du Puy en Velay, Hôpital Emile Roux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre hospitalier de Chambéry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Calydial</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Edouard Herriot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nouvel Hôpital Civil, 1 place de l'Hôpital 67091 Strasbourg cedex</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Lapeyronie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de dialyse d'Alès</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Saint-Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre hospitalier de Perpignan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de néphrologie Polyclinique Médipôle Saint-Roch, Rue Ambroise Croizat</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU Hôpital Maison Blanche, 45 Rue Cognacq-Jay 51092 REIMS Cedex</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assessed the efficacy of a combined solution of ethanol (4%)&#xD;
      and low molecular weight heparins LMWH in preventing tunnelled dialysis catheter infection in&#xD;
      chronic hemodialysis patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In France, a central venous catheter is used in 20 to 30% of chronic hemodialysis patients as&#xD;
      the vascular access device. In this patient population the recommended device is a tunnelled&#xD;
      dialysis catheter (TC). TC-related infections (TCI) and TC dysfunctions are two major&#xD;
      complications and are associated with increased antibiotic consumption, hospital stays,&#xD;
      health costs and mortality. Strategies to prevent TCI should target endoluminal biofilm&#xD;
      formation, which is the major cause of long-term catheter colonization.&#xD;
&#xD;
      Unfractionated heparin (UFH), 5000 U/mL, is the standard interdialytic lock solution for the&#xD;
      prevention of TC thrombosis. A lower-UFH concentration (1000U/mL) is associated with similar&#xD;
      catheter patency. However, UFH has no antibiofilm properties. Antibiotic locks decrease the&#xD;
      rate of TCI including TC- related bloodstream infections (TCBSI) and exit-site infection&#xD;
      (ESI). The widespread use of antibiotic lock solutions raises concerns, however, because of&#xD;
      side effects and the risk for the development of antimicrobial-resistant microorganisms.&#xD;
&#xD;
      Ethanol is an inexpensive antiseptic agent with activity against a broad range of bacteria&#xD;
      and fungi commonly involved in TCI. It acts by non-specific protein denaturation and thus is&#xD;
      less likely to promote antimicrobial resistance. Ethanol concentration of 40% v/v is highly&#xD;
      effective in eradicating biofilm and has no significant impact on the integrity of silicone&#xD;
      and polyurethane TCs or on their mechanical properties. A small randomized controlled trial&#xD;
      performed in chronic hemodialysis patients with TC suggests that once-weekly instillation of&#xD;
      an interdialytic ethanol lock is effective in preventing TCBSI. However, ethanol has no&#xD;
      anticoagulant properties and may induce TC dysfunctions when used alone.&#xD;
&#xD;
      Experimental data provide evidence that a combined solution of ethanol and injectable&#xD;
      anticoagulant is a promising lock solution for preventing both TC infections and&#xD;
      dysfunctions. UFH, at whatever concentration, cannot be mixed with ethanol 40% v/v because of&#xD;
      precipitation. ERA-EDTA recommends using low molecular weight heparins (LMWHs) for blood&#xD;
      circuit anticoagulation during dialysis sessions. Like UFH, LMWHs have no antibiofilm&#xD;
      properties. In contrast, LMWHs can be mixed in ethanol 40% v/v with enoxaparin having the&#xD;
      highest solubility, up to 1300 U/mL. Our group demonstrated that ethanol 40% v/v - enoxaparin&#xD;
      400 U/mL is stable, compatible with TC materials and exhibits antibiofilm and anticoagulant&#xD;
      properties in vitro (patent). No clinical studies have previously assessed the efficacy of a&#xD;
      combined solution of ethanol and LMWH in preventing TCI in chronic hemodialysis patients.&#xD;
&#xD;
      Screening Patients eligible to participate in the study will be identified by a clinical&#xD;
      research assistant in each study centre at the beginning of the study and then weekly. Data&#xD;
      recorded in the medical records will be used.&#xD;
&#xD;
      Enrolment Eligible patients, previously identified during the screening procedure, will be&#xD;
      recruited during a routine hemodialysis session by an investigator from centres participating&#xD;
      in this study Randomization Enrolled patients will be randomly assigned in a 1:1 ratio either&#xD;
      to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000&#xD;
      U/mL or citrate 4% w/v depending on which solution is generally used). Random allocation will&#xD;
      be performed by minimization using a computer algorithm. Minimization strata will be the&#xD;
      study centre, the incident or prevalent nature of the TC and in the prevalent group the&#xD;
      existence or not of a previous infection of the TC in place.&#xD;
&#xD;
      Single blind procedure The study will be performed single blind for the patients and the&#xD;
      analysts. The recognisable smell of ethanol and the need to prepare the Ethenox lock solution&#xD;
      rule out blinding of the healthcare staff.&#xD;
&#xD;
      Treatment Study treatment (Ethenox in the intervention group or reference solutions in the&#xD;
      control group: UFH 5000 U/mL or citrate 4% w/v according to usual practice) will be used by&#xD;
      the hemodialysis nurse as TC lock solution after each hemodialysis session with all&#xD;
      successive TCs used during the study.&#xD;
&#xD;
      All the centres participating in the study will use similar hygiene protocols for TC&#xD;
      placement and maintenance in accordance with the guidelines drawn up by the Haute Autorité de&#xD;
      Santé and the Société Française d'Hygiène Hospitalière. Audits will be conducted during the&#xD;
      study to ensure compliance with guidelines.&#xD;
&#xD;
      Study assessments Bacteriological sampling will be performed in accordance with guidelines&#xD;
      for TCI.&#xD;
&#xD;
      A monthly blood sample will be taken as part of the routine care given to the patients.&#xD;
&#xD;
      Data will be collected weekly in an electronic case report form (e-CRF) except endpoint data&#xD;
      for adjudication and serious adverse events, which will be recorded continuously.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first TC infection (TCI)</measure>
    <time_frame>at 1 year</time_frame>
    <description>TCI is a composite endpoint defined by the occurrence of at least one of the three following events:&#xD;
Definitive TC-related bloodstream infection (definitive TCBSI) or Probable TC-related bloodstream infection (probable TCBSI) or TC exit-site infection (ESI). TCI diagnosis and its type (definitive or probable TCBSI or ESI) will be assessed by an endpoint adjudication committee (EAC) according to predefined criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first definitive or probable TCBSI</measure>
    <time_frame>at 1 year</time_frame>
    <description>TCI prevention criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first ESI</measure>
    <time_frame>at 1 year</time_frame>
    <description>TCI prevention criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of definitive or probable TCBSI</measure>
    <time_frame>at 1 year</time_frame>
    <description>TCI prevention criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of ESI</measure>
    <time_frame>at 1 year</time_frame>
    <description>TCI prevention criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prevalence of colonizations of removed TCs for each TC removed</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of TC dysfunctions</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysis dose measured by the dialysis machine</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to TC removal</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first systemic antibiotic treatment for TCI</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration ( type of antibiotic treatment)</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first hospitalization for TCI</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of hospital stays for TCI</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of TCs replaced during the study</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of breaches in TC integrity (TC leakage or disruption)</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of clinical adverse events related to ethanol exposure</measure>
    <time_frame>at 1 year</time_frame>
    <description>Incidence rate of clinical adverse events related to ethanol exposure (tiredness, ethanol taste, headaches, dizziness, nausea, light-headedness, and increase in serum aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase or alkaline phosphatase).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of type II heparin-induced thrombocytopenia.</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of hemorrhages</measure>
    <time_frame>at 1 year</time_frame>
    <description>bleeding or suspected bleeding, qualified as major if associated with a decrease in hemoglobin levels of more than 2g/dL or the need to transfuse at least two units of red blood cells</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Tunnelled Hemodialysis Catheter Infection</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethanol</intervention_name>
    <description>An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin</intervention_name>
    <description>An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  end-stage renal disease&#xD;
&#xD;
          -  chronic hemodialysis/hemodiafiltration at least three times a week&#xD;
&#xD;
          -  functional TC inserted for at least two weeks&#xD;
&#xD;
          -  Social security cover&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien ANIORT</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 10 81</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>0473751081</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Julien ANIORT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>March 7, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>hemodiafiltration</keyword>
  <keyword>tunnelled dialysis catheter</keyword>
  <keyword>interdialytic lock solution</keyword>
  <keyword>preventing tunnelled catheter infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

